Reverse Transcriptase News and Research

RSS

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Is the CDC 10-day COVID-19 quarantine guideline enough?

Researchers at the University of Florida and the Florida Department of Health evaluated test positivity rates for SARS-CoV-2 infection among student contacts. The team found that nine days are not enough to ascertain that the student did not contract the virus.

24 Feb 2021

No evidence of SARS-CoV-2 fusing into the human genome

New data from researchers led by Majid Kazemian from Purdue University refutes claims from recent studies suggesting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could create a host-virus chimeric RNA. Their team found SARS-CoV-2 does not combine with the human genome.

22 Feb 2021

Study maps SARS-CoV-2 infected brains

Researchers in the United States and Canada have mapped the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the brains of people who died from coronavirus disease 2019 (COVID-19).

21 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

High-throughput sequencing could allow detection of new SARS-CoV-2 variants in wastewater

A new study reports the use of metagenomics to detect the virus from wastewater samples, indicating community-level circulating variants that are not yet identified or are present in very low proportions on clinical databases.

15 Feb 2021

The impact of SARS-CoV-2 on pregnancy in Nordic countries

Population-based studies are essential to gain knowledge of the spread and management of this disease. However, most studies on pregnancy during COVID-19 have not been broadly applicable to Nordic populations, like most current COVID-19 research in general.

11 Feb 2021

Metabolomics and machine learning used to identify possible COVID-19 biomarkers

One of the many mysteries still surrounding COVID-19 is why some people experience only mild, flu-like symptoms, whereas others suffer life-threatening respiratory problems, vascular dysfunction and tissue damage.

10 Feb 2021

SARS-CoV-2 B.1.1.7 may soon become the dominant variant in US

A team of scientists from the United States has recently explored the prevalence and transmission dynamics of the B.1.1.7 variant (UK variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States. The study reveals that because of 35-45% increased transmissibility, B.1.1.7 may soon become the US's dominant variant. The study is currently available on the medRxiv* preprint server.

9 Feb 2021

COVID-19 vaccination associated with 3- to 5-fold reduction in viral load

Researchers in Israel report a reduction in viral load in vaccinated individuals.

9 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

Why SARS-CoV-2 B.1.1.7 is more virulent

A new preprint research paper by scientists from Sweden and India attempts to provide a preliminary answer to these questions using computational modeling. The research, which appears on the bioRxiv* server, predicts increased virulence with the new variant. If validated, this could help public health authorities prepare for new variants' possible impact as they emerge.

2 Feb 2021

New platform using green algae tests for SARS-CoV-2 virus

Researchers at the University of California, San Diego, have demonstrated the potential of using green algae to make recombinant viral proteins that could be used in large scale assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

1 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

A new preprint appearing on the medRxiv server describes the changes that occur in numerous antibodies and inflammatory molecules with age and at varying stages, or severity, of the infection and resulting illness. The results may help to predict the risk in individual cases.

26 Jan 2021

Large study finds SARS-CoV-2 viral load is lowest in children

A new study by researchers in the Netherlands confirms the hypothesis that for SARS-CoV-2 infection, higher age is associated with increased viral loads.

19 Jan 2021

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

An interesting new preprint published on the medRxiv server describes an immunosuppressed patient with coronavirus disease 2019 (COVID-19) who continued to shed the virus for an astounding 154 days. During this period, the virus underwent numerous mutations.

19 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

New test detects SARS-CoV-2 in less than 5 mins

A fast and accurate virus detection strategy is very crucial to reduce the rate of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19. The global scientific research community responded to this unprecedented demand in diagnostic testing by developing several detection platforms, the most sensitive of which detect the viral RNA.

10 Jan 2021